Three Things we Learned in our World Preview 2025 Webinar
Every year, I am hugely fortunate to work with our team of experts to create the Evaluate World Preview report. Now in its 18th year, the World Preview offers a data-rich look at the future of the pharmaceutical industry. It’s full of forecast data that help to paint a picture of the shifting sands of […]
How can Pharma Navigate Turbulent Seas? Find out in our World Preview Webinar
The Evaluate World Preview report is a staple of the pharma calendar. The 2025 edition has just been published, marking the 18th year of providing forecast and trend insights to decision makers across the industry. If you’re not familiar with the World Preview, I recommend taking a look. Not only does it provide a wealth […]
Three Things we Learned in our Biotech Commercialization Webinar
The board at Verona Pharma was taking the steps necessary to take its chronic obstructive pulmonary disorder (COPD) drug to market years ahead of its launch in 2024. This long term view was one of the details shared by Verona’s Chief Commercial Officer, Chris Martin during our recent webinar “Going Solo: What’s Driving the Biotech […]
A Blueprint for Biotech Commercialization?
“Think twice, and twice more, before launching your own drug. It is unimaginably difficult and complex”. Those were the words of a biotech CEO I interviewed more than a decade ago. The advice remains sound. Yet today there are tailwinds encouraging more biotechs to take their prized assets all the way to market. (And let’s […]
Three Things we Learned in our “First to Market Myth” Webinar
It is a truth universally acknowledged that a new market in possession of unmet need will reward its first entrant with commercial advantage. Except, that “truth” may be somewhat overstated. This was the topic of our recent webinar, “The First to Market Myth: What Really Drives Launch Success?”. During the session, Evaluate consultants Mark Lansdell, […]
Should Pharma Companies Really Race to be First to Market?
For Portfolio Strategy teams in pharma companies, there is a constant juggling act to ensure that the right therapies are being prioritized for the right indications. This requires a clear understanding of the potential market size, payer perspectives and competitive environment. With the right data and insight, you can plan your go-to-market approach – and […]
Three Things we Learned in our Mastering Long-Range Planning Processes Webinar
Our webinar on Long-Range Planning (LRP) forecasting took place recently and – as always – our experts Andrew Ward and Amanda Randall were on fine form. Full disclosure – this was our second webinar on this topic. You can catch up with part one – The Forecaster’s Guide to Long Range Planning here. The session […]
What makes a good (and bad) pharmaceutical forecast model
Having good forecast models is critical for effective and efficient decision-making. This will deliver accurate and reliable insights to help support business objectives and drive brand or company growth, highlight risk, and quantify opportunity. This article explores the key ingredients needed for developing good pharmaceutical forecast models. It’s widely accepted that there is no such […]
How can you Improve Efficiencies in your Long-Range Planning?
No element of pharmaceutical forecasting is easy but there’s a particular challenge in long-range planning. The range of components involved results in a greater degree of complexity which can allow inaccuracies to creep in very easily. We covered some of the key challenges in a recent webinar, The Forecaster’s Guide to Long-Range Planning, which you […]
Three Things We Learned in Our Orphan Drugs Webinar
Our recent orphan drugs webinar provided a wealth of insights into the current state and future of the orphan drug market. It was based on our annual report (which is available here) and if you missed it, I recommend taking the time to watch the on-demand version. Our panel included the report’s author, Melanie Senior […]
